截至2026年1月9日收盘，神州细胞（688520）报收于49.16元，较上周的43.31元上涨13.51%。本周，神 州细胞1月9日盘中最高价报49.38元。1月5日盘中最低价报43.18元。神州细胞当前最新总市值218.93亿 元，在生物制品板块市值排名14/51，在两市A股市值排名959/5182。 本周关注点 公司公告汇总：神州细胞2025年度向特定对象发行股票获中国证监会同意注册批复。 公司公告汇总 神州细胞关于2025年度向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的公告 北京神州细胞生物技术集团股份公司于近日收到中国证券监督管理委员会出具的《关于同意北京神州细 胞生物技术集团股份公司向特定对象发行股票注册的批复》（证监许可〔2025〕2971号），同意公司向 特定对象发行股票的注册申请。批复自同意注册之日起12个月内有效。公司将在规定期限内办理发行相 关事项，并及时履行信息披露义务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

当日关注点 截至2026年1月6日收盘，神州细胞(688520)报收于46.51元，下跌0.83%，换手率0.8%，成交量3.56万 手，成交额1.64亿元。 神州细胞关于2025年度向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的公告 北京神州细胞生物技术集团股份公司于近日收到中国证券监督管理委员会出具的《关于同意北京神州细 胞生物技术集团股份公司向特定对象发行股票注册的批复》（证监许可〔2025〕2971号），同意公司向 特定对象发行股票的注册申请。批复自同意注册之日起12个月内有效。公司将在规定期限内办理发行相 关事项，并及时履行信息披露义务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月6日主力资金净流出1112.55万元，游资资金净流入1042.54万元。 来自公司公告汇总：神州细胞2025年度向特定对象发行股票申请获证监会同意注册批复，批复有 效期12个月。 交易信息汇总 资金流向 1月6日主力资金净流出1112.55万元；游资资金净流入1042.54万元；散户资金净流入70.01 ...

证券之星消息，1月6日生物制品板块较上一交易日上涨0.55%，辽宁成大领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600739 | 辽宁成大 | 12.27 | 7.16% | 53.05万 | 6.33亿 | | 300239 | 东宝生物 | 6.18 | 5.64% | 45.45万 | 2.78亿 | | 616889 | 欧林生物 | 27.66 | 3.83% | 7.44万 | 2.04亿 | | 002773 | 康弘药业 | 33.75 | 2.37% | 24.97万 | 8.38亿 | | 920547 | 无锡晶海 | 24.50 | 2.30% | 7683.33 | 1866.29万 | | 688137 | 近岸蛋白 | 41.66 | 1.36% | 5192.83 | 2149.33万 | | 000661 | 长春高新 | 9 ...

Core Viewpoint - Beijing Sinocell Biotechnology Group Co., Ltd. has received approval from the China Securities Regulatory Commission for its application to issue shares to specific investors for the year 2025 [1][3]. Group 1 - The company has been granted registration approval for the issuance of shares to specific investors, as per the approval document issued by the China Securities Regulatory Commission [1]. - The issuance must strictly follow the declaration documents and issuance plan submitted to the Shanghai Stock Exchange [2]. - The approval is valid for 12 months from the date of registration consent, and the company must report any significant events to the Shanghai Stock Exchange before the issuance is completed [3]. Group 2 - The company’s board will handle the issuance matters within the stipulated timeframe and fulfill information disclosure obligations as required by the approval document and relevant laws [3]. - Contact information for the company and its sponsor (lead underwriter) is provided for investor inquiries [4]. - The announcement was made by the board of directors of Beijing Sinocell Biotechnology Group Co., Ltd. on January 6, 2026 [5].

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is seeking public opinions on the draft guidelines for the real-world comprehensive value assessment of medical services, aiming to establish a unified evaluation system across the country [1] - CanSino Biologics has received approval for clinical trials of its 24-valent pneumococcal polysaccharide conjugate vaccine, which targets major circulating serotypes and is intended for individuals aged 2 months and older [2] - Merck has announced that its breakthrough therapy, Sotatercept, has been approved in China for treating adult patients with pulmonary arterial hypertension (PAH), based on data from the STELLAR Phase III clinical trial [3] - ST. Renfu has received approval for clinical trials of HW221043 tablets, intended for the treatment of advanced solid tumors, with no similar drugs currently approved in the market [4] - Heng Rui Medicine has received approval for clinical trials of HRS-4357 injection and HRS-5041 tablets, aimed at treating PSMA-positive prostate cancer [5] Group 2: Market Activities - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [6] - Tianchen Medical has signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical intelligent manufacturing and robotics [7] - Zhonghong Medical's subsidiary has participated in a bidding project for centralized procurement of medical consumables, with some products expected to be selected, enhancing market presence [8] - Yifan Pharmaceutical's subsidiary has signed an exclusive agreement with Shangde Yaoyuan for the ACT001 drug, involving a total payment of 1 billion yuan [9] - Yijiahe is exploring the application of "brain-computer interface + embodied intelligent robots" technology in smart healthcare scenarios, having signed a strategic cooperation agreement with Mairande [10]

最新公告列表 《神州细胞关于2025年度向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的 公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月5日收盘，神州细胞（688520）报收于46.9元，较前一交易日上涨8.29%，最新总市值为 208.86亿元。该股当日开盘43.25元，最高47.25元，最低43.18元，成交额达2.88亿元，换手率为1.41%。 公司近日发布公告称，北京神州细胞生物技术集团股份公司于近日收到中国证券监督管理委员会出具的 《关于同意北京神州细胞生物技术集团股份公司向特定对象发行股票注册的批复》（证监许可〔2025〕 2971号），同意公司向特定对象发行股票的注册申请。批复自同意注册之日起12个月内有效。公司将在 规定期限内办理发行相关事项，并及时履行信息披露义务。 ...

神州细胞(688520.SH)发布公告，公司于近日收到中国证券监督管理委员会出具的《关于同意北京神州 细胞生物技术集团股份公司向特定对象发行股票注册的批复》(证监许可〔2025〕2971号)，同意公司向 特定对象发行股票的注册申请。 ...

智通财经APP讯，神州细胞(688520.SH)发布公告，公司于近日收到中国证券监督管理委员会出具的 《关于同意北京神州细胞生物技术集团股份公司向特定对象发行股票注册的批复》(证监许可〔2025〕 2971号)，同意公司向特定对象发行股票的注册申请。 ...

据了解，神州细胞本次发行募集资金总额不超过9亿元（含本数），扣除发行费用后拟全部用于补充流 动资金。 北京商报讯（记者 丁宁）1月5日晚间，神州细胞（688520）发布公告称，公司于近日收到中国证监会 出具的《关于同意北京神州细胞生物技术集团股份公司向特定对象发行股票注册的批复》，证监会同意 公司向特定对象发行股票的注册申请。 ...

Core Viewpoint - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [1] Group 1 - The company announced on January 5 that it has received a formal approval from the regulatory authority [1] - The approval pertains to the company's registration application for issuing stocks to specific targets [1]